Sachie Marubayashi
Pulse Biosciences (United States)(US)
Publications by Year
Research Areas
Myeloproliferative Neoplasms: Diagnosis and Treatment, Cytokine Signaling Pathways and Interactions, Chronic Myeloid Leukemia Treatments, Cancer Immunotherapy and Biomarkers, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy(2012)362 cited
- → A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms(2009)343 cited
- → JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response(2015)306 cited
- → HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans(2010)179 cited
- → Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition(2012)162 cited
- → Tumors establish resistance to immunotherapy by regulating Tregrecruitment via CCR4(2020)136 cited
- → Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms(2014)109 cited
- → Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis(2010)78 cited
- → Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis(2014)51 cited
- → Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias(2015)40 cited